A Unique Factor XIII Mutation in Southeastern Iran with an Unexpectedly High Prevalence: Khash Factor XIII

Akbar Dorgalaleh; Shadi Tabibian; Mahmood Shams; Golbahar Majid; Majid Naderi; Alessandro Casini; Behnaz Tavasoli; Maryam Gheidishiran; Maryam Daneshi; Majid Safa

doi:10.1055/s-0038-1676580

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2019; 45(01): 043-049
DOI: 10.1055/s-0038-1676580

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Unique Factor XIII Mutation in Southeastern Iran with an Unexpectedly High Prevalence: Khash Factor XIII

Authors

Akbar Dorgalaleh

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Shadi Tabibian

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Mahmood Shams

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Golbahar Majid

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Majid Naderi

²Department of Pediatrics Hematology and Oncology, Ali Ebn-e Abitaleb Hospital Research Center for Children and Adolescents Health (RCCAH), Zahedan University of Medical Sciences, Zahedan, Iran
Alessandro Casini

³Division of Angiology and Haemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland
Behnaz Tavasoli

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Maryam Gheidishiran

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Maryam Daneshi

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Majid Safa

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

Abstract

Congenital factor XIII (FXIII) deficiency is an extremely rare hemorrhagic disorder characterized by a deficiency of FXIII and associated with a high rate of morbidity and mortality. The disorder is more frequent in Iran, especially in Khash, a city in the southeast of the country. As identified in the current report, the prevalence of FXIII deficiency in this city is 1 homozygote per approximately 500 population (which is ∼4,000 times higher than the worldwide prevalence) with 3.5% heterozygotes. The disorder is accompanied by a high rate of mortality in rural areas of Khash, given an averaged observed rate of approximately three deaths per each family with FXIII deficiency, mostly due to late-diagnosis and/or misdiagnosis, and fetal consequences of both umbilical cord and central nervous system bleeding. Almost all patients with FXIII deficiency in the southeast Iran have a unique mutation in F13A gene (Trp187Arg), which leads to a severe FXIII deficiency. This mutation is used for pre-marriage and prenatal diagnosis, as well as for carrier detection and diagnostic confirmation. Fibrogammin P has been used worldwide for about one decade, along with different therapeutic regimens for prophylaxis treatment, major and minor surgeries, and successful delivery. Due to the rapid increase in the number of patients identified to have congenital FXIII deficiency, and the high rate of related morbidity and mortality, a comprehensive regional preventive program is necessary to prevent further expansion of this condition and decrease the burden on the health care system. The area of Khash city provides novel insights into severe FXIII deficiency due to its high prevalence in this region. This report also provides a review of FXIII deficiency, its diagnosis, prevalence, molecular basis, clinical manifestations, management, and treatment, with a particular focus on Iran, representing a hotspot for this disorder.

Keywords

factor XIII deficiency - Khash city - southeastern Iran - morbidity - mortality

Full Text

References

References
1 Acharya SS, Coughlin A, Dimichele DM. ; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2 (02) 248-256
2 Dorgalaleh A, Naderi M, Hosseini MS. , et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost 2015; 41 (03) 323-329
3 Anwar R, Minford A, Gallivan L, Trinh CH, Markham AF. Delayed umbilical bleeding--a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics 2002; 109 (02) E32
4 Muszbek L, Katona É. Diagnosis and management of congenital and acquired FXIII deficiencies. Semin Thromb Hemost 2016; 42 (04) 429-439
5 Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol 2016; 95 (03) 451-455
6 Dorgalaleh A, Tabibian S, Shams M. , et al. Von Willebrand disease in Iran: diagnosis and management. Ann Blood 2018; 3 (01) 1-11
7 Dorgalaleh A, Dadashizadeh G, Bamedi T. Hemophilia in Iran. Hematology 2016; 21 (05) 300-310
8 Ivaskevicius V, Seitz R, Kohler HP. , et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (06) 914-921
9 Dorgalaleh A, Assadollahi V, Tabibian S, Shamsizadeh M. Molecular basis of congenital factor XIII deficiency in Iran. Clin Appl Thromb Hemost 2018; 24 (02) 210-216
10 Anwar R, Gallivan L, Miloszewski KJ, Markham AF. Factor XIII deficiency causing mutation, Ser295Arg, in exon 7 of the factor XIIIA gene. Thromb Haemost 2000; 84 (04) 591-594
11 Mikkola H, Syrjälä M, Rasi V. , et al. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 1994; 84 (02) 517-525
12 Mikkola H, Muszbek L, Haramura G, Hämäläinen E, Jalanko A, Palotie A. Molecular mechanisms of mutations in factor XIII A-subunit deficiency: in vitro expression in COS-cells demonstrates intracellular degradation of the mutant proteins. Thromb Haemost 1997; 77 (06) 1068-1072
13 Vysokovsky A, Saxena R, Landau M. , et al. Seven novel mutations in the factor XIII A-subunit gene causing hereditary factor XIII deficiency in 10 unrelated families. J Thromb Haemost 2004; 2 (10) 1790-1797
14 El Mahmoudi H, Amor MB, Gouider E. , et al. Small insertion (c.869insC) within F13A gene is dominant in Tunisian patients with inherited FXIII deficiency due to ancient founder effect. Haemophilia 2009; 15 (05) 1176-1179
15 Dorgalaleh A, Tabibian S, Hosseini S, Shamsizadeh M. Guidelines for laboratory diagnosis of factor XIII deficiency. Blood Coagul Fibrinolysis 2016; 27 (04) 361-364
16 Gheidishahran M, Dorgalaleh A, Tabibian S. , et al. Molecular diagnosis of factor XIII deficiency, data from comprehensive coagulation laboratory in Iran. Blood Coagul Fibrinolysis 2018; 29 (01) 87-91
17 Dorgalaleh A, Tabibian S, Assadollahi V. , et al. Comparison of 2 methods of clot solubility testing in detection of factor XIII deficiency. Lab Med 2016; 47 (04) 283-285
18 Jennings I, Kitchen S, Woods TA, Preston FE. ; UK NEQAS. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost 2003; 1 (12) 2603-2608
19 Alavi SER, Jalalvand M, Assadollahi V, Tabibian S, Dorgalaleh A. Intracranial hemorrhage: a devastating outcome of congenital bleeding disorders-prevalence, diagnosis, and management, with a special focus on congenital factor XIII deficiency. Semin Thromb Hemost 2018; 44 (03) 267-275
20 Dorgalaleh A, Tabibian SH, Safa M, Shams M, Naderi M. Minimal factor XIII activity level to prevent major spontaneous bleeds: comment. J Thromb Haemost 2017; 15 (11) 2279-2280
21 Dorgalaleh A, Alavi SER, Tabibian S. , et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology 2017; 22 (04) 224-230
22 Carcao M, Fukutake K, Inbal A. , et al. Developing the first recombinant factor XIII for congenital factor XIII deficiency: clinical challenges and successes. Semin Thromb Hemost 2017; 43 (01) 59-68
23 Lassila R. Clinical use of factor XIII concentrates. Semin Thromb Hemost 2016; 42 (04) 440-444
24 Eshghi P, Abolghasemi H, Sanei-Moghaddam E. , et al. Factor XIII deficiency in south-east Iran. Haemophilia 2004; 10 (05) 470-472
25 Naderi M, Alizadeh S, Tabibian S. , et al. Letter to the editor: effect of social factors on the highest global incidence of congenital factor XIII deficiency in southeast of Iran. Arch Iranian Med 2015; 18 (05) 331
26 Hosseini S, Dorgalaleh A, Bamedi T. , et al. First cases of severe congenital factor XIII deficiency in Southwestern Afghanistan in the vicinity of southeast of Iran. Blood Coagul Fibrinolysis 2015; 26 (08) 908-911
27 Trinh CH, Sh Elsayed W, Eshghi P. , et al. Molecular analysis of sixteen unrelated factor XIIIA deficient families from south-east of Iran. Br J Haematol 2008; 140 (05) 581-584
28 Li B, Borhany M, Abid M, Kohler HP, Schroeder V. Identification of a novel nonsense mutation leading to congenital factor XIII deficiency. Thromb Res 2018; 165: 83-85
29 Dorgalaleh A, Tabibian S, Varmaghani B, Tamaddon GH, Boustani H. 559 T> C as the most common mutation of factor XIII deficiency in Iranian patients is not restricted to Southeast Iran. J Cellular Mol Anesth 2016; 1 (04) 154-157
30 Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016; 30 (06) 461-475
31 Naderi M, Dorgalaleh A, Peyman E, Malek F, Karimi M. A large-scale prospective cohort study on factor XIII deficiency in Southeast of Iran. Am Soc Hematol 2016; 128 (22) 209
32 Naderi M, Eshghi P, Saneei Moghaddam E. , et al. Safety of human blood products in rare bleeding disorders in southeast of Iran. Haemophilia 2013; 19 (02) e90-e92
33 Naderi M, Ahmadinejad M, Hosseini MS, Moradi E, Dorgalaleh A, Shamsizadeh M. Long-term prophylaxis in patients with severe congenital factor XIII deficiency is not complicated by inhibitor formation. Blood Coagul Fibrinolysis 2017; 28 (04) 276-278
34 Naderi M, Haghpanah S, Miri-Aliabad G, Tavosi H, Karimi M. A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran. J Thromb Haemost 2017; 15 (12) 2300-2305
35 Dorgalaleh A, Motlagh H, Tabibian S, Majid N. Burden of congenital factor XIII deficiency in Iran. J Cell Mol Anesth 2017; 2 (03) 142-145
36 Naderi M, Reykande SE, Dorgalaleh A. , et al. Establishment of a prenatal diagnosis schedule as part of a prophylaxis program of factor XIII deficiency in the southeast of Iran. Blood Coagul Fibrinolysis 2016; 27 (01) 97-100